The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 501–600 of 1,029
Aqueous polymer two‐phase systems: Effective tools for plasma membrane proteomics
Schindler, J., & Nothwang, H. G. (2006) · PROTEOMICS · doi:10.1002/pmic.200600243 · Cited by 113
Minimum information about a bioactive entity (MIABE)
Orchard, S., Al-Lazikani, B., Bryant, S., Clark, D., Calder, E., Dix, I., Engkvist, O., Forster, M., Gaulton, A., Gilson, M., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3503 · Cited by 98
Self-citationKume, H., Muraoka, S., Kuga, T., Adachi, J., Narumi, R., Watanabe, S., Kuwano, M., Kodera, Y., Matsushita, K., Fukuoka, J., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.037093 · Cited by 113
“Membrane proteins play critical roles in many biological functions, such as signal transduction, cell-cell interactions, and ion transport, account for 38% of all proteins encoded by the mammalian genome and more than one-third of biomarker candidates, and are also potential targets for drug therapy (6, 7).”
BackgroundTarget Repurposing for Neglected Diseases
Pollastri, M. P., & Campbell, R. K. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.92 · Cited by 103
“A further challenge to any drug-discovery program is the assumption that a proposed therapeutic target is ‘druggable’, meaning that is can be manipulated for therapeutic effect by drug-like molecules [6].”
BackgroundTherapeutic Potential of Small Molecules and Engineered Proteins
Gurevich, E. V., & Gurevich, V. V. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-41199-1_1 · Cited by 92
“For example, in case of GPCRs, which are targeted by >30 % of clinically used drugs (Hopkins and Groom 2002), the agonists promote receptor interactions with heterotrimeric G proteins (Samama et al. 1993), then GPCR kinases (GRKs) (Gurevich et al. 2012), and then arrestins (Gurevich and Gurevich…”
BackgroundInfluentialHost proteins involved in HIV infection: New therapeutic targets
Arhel, N. J., & Kirchhoff, F. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.003 · Cited by 118
Regulators of G-Protein Signaling in the Heart and Their Potential as Therapeutic Targets
Zhang, P., & Mende, U. (2011) · Circulation Research · doi:10.1161/circresaha.110.231423 · Cited by 100
Sorolla, A., Wang, E., Golden, E., Duffy, C., Henriques, S. T., Redfern, A. D., & Blancafort, P. (2019) · Oncogene · doi:10.1038/s41388-019-1056-3 · Cited by 104
“Additionally, more than 90% of human proteins are intracellular or secreted, which makes them difficult to bind by therapeutics that largely target cell surface proteins [5].”
BackgroundZhou, D., Xu, Z., Li, W., Xie, X., & Peng, S. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab473 · Cited by 105
Molecular chameleons in drug discovery
Poongavanam, V., Wieske, L. H. E., Peintner, S., Erdélyi, M., & Kihlberg, J. O. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00563-1 · Cited by 107
G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease
Divorty, N., Mackenzie, A. E., Nicklin, S. A., & Milligan, G. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00041 · Cited by 104
“G protein-coupled receptors are historically the most successful group of drug targets, and account for some 30–40% of approved drugs on the market today (Drews, 2000; Hopkins and Groom, 2002; Rask-Andersen et al., 2011).”
BackgroundNew Protein Kinase CK2 Inhibitors: Jumping out of the Catalytic Box
Prudent, R., & Cochet, C. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.01.004 · Cited by 98
Membrane proteins ride shotgun
Rabilloud, T. (2003) · Nature Biotechnology · doi:10.1038/nbt0503-508 · Cited by 98
Mustafi, D., & Palczewski, K. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.051938 · Cited by 95
“Even though 30% of all marketed therapeutics act on GPCRs (Hopkins and Groom, 2002), these drugs target only 30 members of this class, so there is enormous potential to exploit the remaining family members, including the 100 orphan receptors (Civelli, 2005), for which no existing ligands have yet…”
BackgroundMining Predicted Essential Genes of Brugia malayi for Nematode Drug Targets
Kumar, S., Chaudhary, K., Foster, J. M., Novelli, J. F., Zhang, Y., Wang, S., Spiro, D., Ghedin, E., & Carlow, C. K. S. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001189 · Cited by 106
“Proteins with LR5 druggable domains or druggable EC numbers were given a high priority.”
BackgroundInfluentialComputational Prediction of Protein Hot Spot Residues
Kenneth Morrow, J., & Zhang, S. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436412 · Cited by 98
“One significant part of this problem is the nature of the PPIs; classic protein inhibitors primarily target well -defined grooves and pockets [21, 22], whereas PPIs are usually large and relatively planar surfaces that were originally considered not conducive to druggability by “drug-like”…”
Fine-Tuning Multiprotein Complexes Using Small Molecules
Thompson, A. D., Dugan, A., Gestwicki, J. E., & Mapp, A. K. (2012) · ACS Chemical Biology · doi:10.1021/cb300255p · Cited by 92
“01% have been targeted with inhibitors (2, 6-8).”
BackgroundInfluentialA human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs
Karlas, A., Berrè, S., Couderc, T., Varjak, M., Braun, P. R., Meyer, M., Gangneux, N., Karo-Astover, L., Weege, F., Raftery, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11320 · Cited by 106
Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space
Poongavanam, V., Doak, B. C., & Kihlberg, J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.010 · Cited by 95
Vogel, S. M., Bauer, M. R., & Boeckler, F. M. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci2001549 · Cited by 94
Hydrophobicity scales: a thermodynamic looking glass into lipid–protein interactions
MacCallum, J. L., & Tieleman, D. P. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.08.003 · Cited by 103
Stapling of unprotected helical peptides via photo-induced intramolecular thiol–yne hydrothiolation
Tian, Y., Li, J., Zhao, H., Zeng, X., Wang, D., Liu, Q., Niu, X., Huang, X., Xu, N., & Li, Z. (2016) · Chemical Science · doi:10.1039/c6sc00106h · Cited by 97
Fluorine-19 NMR of integral membrane proteins illustrated with studies of GPCRs
Didenko, T., Liu, J. J., Horst, R., Stevens, R. C., & Wüthrich, K. (2013) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2013.07.011 · Cited by 96
Lim, F. P. L., & Dolzhenko, A. V. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.112 · Cited by 96
Järvinen, A.-K., Autio, R., Haapa-Paananen, S. M., Wolf, M., Saarela, M., Grenman, R. A., Leivo, I. V. V., Kallioniemi, O., Mäkitie, A. A., & Monni, O. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209690 · Cited by 106
“…many signal transduction pathways; transmembrane receptors (GO:0004888), which are currently targets of many marketed drugs (e.g. G-protein-coupled receptors); peptidases (GO:0008233), or genes with catalytic activity (GO:0003824, enzymes) (Hopkins and Groom, 2002) (Supplementary Tables 6 and 7).”
BackgroundLessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
“creates another hurdle to applying target-based screen approaches [41,42].”
BackgroundRecent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 101
Non-invasive optical biosensor for assaying endogenous G protein-coupled receptors in adherent cells
Ye, F., Li, G., & Ferrie, A. M. (2006) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2006.11.001 · Cited by 107
An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics
Duncan, J. S., Gyenis, L., Lenehan, J. G., Bretner, M., Graves, L. M., Haystead, T., & Litchfield, D. W. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700559-mcp200 · Cited by 95
“Recently protein kinases have emerged as some of the most promising drug targets, representing as much as 20% of the “druggable” genome (2, 3).”
BackgroundMass spectrometry-enabled structural biology of membrane proteins
Calabrese, A. N., & Radford, S. E. (2018) · Methods · doi:10.1016/j.ymeth.2018.02.020 · Cited by 92
Reaction development for DNA-encoded library technology: From evolution to revolution?
Götte, K., Chines, S., & Brunschweiger, A. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.151889 · Cited by 94
Human embryonic stem cells: Current technologies and emerging industrial applications
Améen, C., Strehl, R., Björquist, P., Lindahl, A. H., Hyllner, J., & Sartipy, P. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.012 · Cited by 104
“In fact, the 100 top selling drugs in 001 were directed at only 43 host proteins [223].”
BackgroundHigh‐order combination effects and biological robustness
Lehár, J., Krueger, A., Zimmermann, G., & Borisy, A. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.51 · Cited by 95
“In humans, this robustness is reflected in the fact that many drug candidates discovered using the prevailing one-drug-one-target paradigm fail because of a lack of efficacy (Hopkins and Groom, 2002).”
Validation strategies for target prediction methods
Mathai, N., Chen, Y., & Kirchmair, J. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz026 · Cited by 101
“being able to modulate a target’s activity with a small molecule [63, 64], may also be an indicator of how difficult it is, in particular for a docking algorithm, to make predictions for a specific target.”
BackgroundIntracellular Protein Delivery: Approaches, Challenges, and Clinical Applications
Chan, A., & Tsourkas, A. (2024) · BME Frontiers · doi:10.34133/bmef.0035 · Cited by 99
“This so-called undruggable proteome is estimated to encompass 80% of known genes [4–7].”
BackgroundSable, R. V., & Jois, S. D. S. (2015) · Molecules · doi:10.3390/molecules200611569 · Cited by 102
Multiple cyclophilins involved in different cellular pathways mediate HCV replication
Gaither, L. A., Borawski, J. A., Anderson, L. J., Balabanis, K. A., Dévay, P., Joberty, G., Rau, C., Schirle, M., Bouwmeester, T., Mickanin, C., et al. (2009) · Virology · doi:10.1016/j.virol.2009.10.043 · Cited by 93
IRES-Mediated Translation of Membrane Proteins and Glycoproteins in Eukaryotic Cell-Free Systems
Brödel, A. K., Sonnabend, A., Roberts, L. O., Stech, M., Wüstenhagen, D. A., & Kubick, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082234 · Cited by 94
“As glycoproteins and membrane proteins are of special pharmaceutical interest [21,22], the work particularly highlights the cell-free expression of these types of proteins.”
BackgroundEvers, A., & Klebe, G. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200352776 · Cited by 93
Global vision of druggability issues: applications and perspectives
Hussein, H. A., Geneix, C., Petitjean, M., Borrel, A., Flatters, D., & Camproux, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.021 · Cited by 102
Adenoviral Vectors Expressing siRNAs for Discovery and Validation of Gene FunctionPreprint
Arts, G., Langemeijer, E., Tissingh, R., Ma, L., Pavliska, H., Dokic, K., Dooijes, R., Mešić, E., Clasen, R., Michiels, F., et al. (2003) · Genome Research · doi:10.1101/gr.1332603 · Cited by 92
“We are presently using the adenoviral vector for the construction of a library that covers all genes that belong to druggable gene classes (Hopkins and Groom 2002).”
MethodNetwork-based characterization of drug-regulated genes, drug targets, and toxicity
Kotlyar, M., Fortney, K., & Jurisica, I. (2012) · Methods · doi:10.1016/j.ymeth.2012.06.003 · Cited by 92
Ellingson, S. R., Smith, J. C., & Baudry, J. Y. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23367 · Cited by 98
Allosteric targeting of receptor tyrosine kinases
Smet, F. D., Christopoulos, A., & Carmeliet, P. (2014) · Nature Biotechnology · doi:10.1038/nbt.3028 · Cited by 102
RNA –ligand molecular docking: Advances and challenges
Zhou, Y., Jiang, Y., & Chen, S. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1571 · Cited by 110
“19 – 21 The availability of druggable protein targets is further restricted by the structural and energetic fitness required for high-affinity drug binding.”
BackgroundLessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Lackey, K. E. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743156 · Cited by 92
Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy
Gowda, R., Jones, N. R., Banerjee, S., & Robertson, G. P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000184 · Cited by 95
“While there has been success in rational drug design for cancer therapy, only a few pathways are druggable with current chemistries [33,34].”
BackgroundSelenium binding protein 1 in ovarian cancer
Huang, K., Park, D. C., Ng, S., Lee, J. Y., Ni, X., Ng, N., Bandera, C. A., Welch, W. R., Berkowitz, R. S., Mok, S. C., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21671 · Cited by 92
“Membrane-associated proteins have been suggested to be a potential resource for biomarker screening.(6) In our pilot study of the use of 2-D PAGE to profile membrane-associated proteins of normal ovarian surface epithelial cells and ovarian cancer cell lines, selenium binding protein 1 (SELENBP1) was identified as the…”
BackgroundPharmacophylogenomics: genes, evolution and drug targets
Searls, D. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1152 · Cited by 99
The sea urchin kinome: A first look
Bradham, C. A., Foltz, K. R., Beane, W. S., Arnone, M. I., Rizzo, F. M., Coffman, J. A., Mushegian, A. R., Goel, M., Morales, J., Genevière, A., et al. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.08.074 · Cited by 96
“Kinases are the most frequently targeted gene class in cancer therapeutics, and are second only to G protein-coupled receptors across all therapeutic areas (Cohen, 2002; Hopkins and Groom, 2002), illustrating their importance in both disease and pharmacology.”
BackgroundPoongavanam, V., Danelius, E., Peintner, S., Alcaraz, L., Caron, G., Cummings, M. D., Wlodek, S. T., Erdélyi, M., Hawkins, P. C. D., Ermondi, G., et al. (2018) · ACS Omega · doi:10.1021/acsomega.8b01379 · Cited by 100
Wu, X., Luo, Q., & Liu, Z. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02760-y · Cited by 99
“However, ~80% of proteins in human cells cannot be targeted pharmacologically and are de fi ned as “ undruggable ” 130 .”
Pocket-Based Drug Design: Exploring Pocket Space
Zheng, X., Gan, L., Wang, E., & Wang, J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9426-6 · Cited by 101
“Although druggability is still a debatable concept (35), it is currently a hot topic in the review literature (1,3,4,9,36).”
BackgroundRegulation of cell proliferation and survival: Convergence of protein kinases and caspases
Duncan, J. S., Turowec, J. P., Vilk, G., Li, S. S. ‐., Gloor, G. B., & Litchfield, D. W. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.11.001 · Cited by 96
Protein Kinase CK2 in Health and Disease
Battistutta, R. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-9155-x · Cited by 95
High-throughput electronic biology: mining information for drug discovery
Loging, W., Harland, L., & Williams–Jones, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2265 · Cited by 105
“For small-molecule discovery, an assessment of the likelihood of obtaining a lead chemical matter (termed druggabilit”
BackgroundFrench Swimwear for Membrane Proteins
Sanders, C. R., Hoffmann, A. K., Gray, D. N., Keyes, M. H., & Ellis, C. D. (2004) · ChemBioChem · doi:10.1002/cbic.200300830 · Cited by 91
Díaz-González, R., Kuhlmann, F. M., Galan-Rodriguez, C., da Silva, L. M., Saldivia, M., Karver, C. E., Rodríguez, A., Beverley, S. M., Navarro, M., & Pollastri, M. P. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001297 · Cited by 92
“likely ‘‘druggable’’ [12], that is, that compounds can be designed”
Kollmann, C. S., Bai, X., Tsai, C.-H., Yang, H., Lind, K. E., Skinner, S. R., Zhu, Z., Israel, D. I., Cuozzo, J. W., Morgan, B. A., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.01.050 · Cited by 91
Therapeutics—how to treat phase separation-associated diseases
Wheeler, R. J. (2020) · Emerging Topics in Life Sciences · doi:10.1042/etls20190176 · Cited by 99
Sulfatase-Induced In Situ Formulation of Antineoplastic Supra-PROTACs
Chen, N., Zhang, Z., Liu, X., Wang, H., Guo, R.-C., Wang, H., Hu, B., Shi, Y., Zhang, P., Liu, Z., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c00826 · Cited by 93
Chemical, Target, and Bioactive Properties of Allosteric Modulation
van Westen, G. J. P., Gaulton, A., & Overington, J. P. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003559 · Cited by 85
Human monogenic disorders — a source of novel drug targets
Brinkman, R. R., Dubé, M., Rouleau, G. A., Orr, A. C., & Samuels, M. E. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1828 · Cited by 93
Ethanol-enhanced GABA release: A focus on G protein-coupled receptors
Kelm, M. K., Criswell, H. E., & Breese, G. R. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.09.003 · Cited by 88
“If future pharmacotherapy options for alcohol use disorders are based upon a change in GABA release, the strategy will likely involve modulation of a GPCR, as do approximately 30% of all marketed prescription drugs (Hopkins and Groom, 2002).”
Predicting and Experimentally Validating Hot-Spot Residues at Protein–Protein Interfaces
Ibarra, A. Á., Bartlett, G. J., Hegedüs, Z., Dutt, S., Hóbor, F., Horner, K. A., Hetherington, K., Spence, K., Nelson, A. S., Edwards, T. A., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00560 · Cited by 112
Has the yo‐yo stopped? An assessment of human protein‐coding gene number
Southan, C. (2004) · PROTEOMICS · doi:10.1002/pmic.200300700 · Cited by 112
Spatiotemporal identification of druggable binding sites using deep learning
Kozlovskii, I., & Popov, P. (2020) · Communications Biology · doi:10.1038/s42003-020-01350-0 · Cited by 89
Oncogenes and tumor suppressor genes: comparative genomics and network perspectives
Zhu, K., Liu, Q., Zhou, Y., Tao, C., Zhao, Z., Sun, J., & Xu, H. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s7-s8 · Cited by 106
“Among these risk factors, genetic alternations play critical roles in the pathogenesis of the disease and provide fundamental clues for the identification of drug targets and the development of novel drugs [2-6].”
BackgroundZuo, H., Zhang, Q., Su, S.-B., Chen, Q., Yang, F. Q., & Yuanjia, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-29764-1 · Cited by 96
Fontaine, F., Overman, J., & François, M. (2015) · Cell Regeneration · doi:10.1186/s13619-015-0015-x · Cited by 86
“It is now widely admitted that a large majority of the estimated 3,000 druggable proteins [3] function as com-”
BackgroundInfluentialGanapathy‐Kanniappan, S., Kunjithapatham, R., & Geschwind, J.-F. H. (2012) · Oncotarget · doi:10.18632/oncotarget.623 · Cited by 97
“Although, it has been estimated that at least 2-5% of the human genome (among ~30,000 genes) may form potential therapeutic targets [1], the key requirements of “druggability”, in the interests of pharmaceutical industry or any drugdevelopment programs, restrict the number dramatically into fewer candidates.”
BackgroundBiophysical Screening for the Discovery of Small-Molecule Ligands
Ciulli, A. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-398-5_13 · Cited by 105
“In parallel, recent advances in our molecular understanding of many diseases have revealed many new potential targets for small-molecule intervention, significantly expanding the druggable genome (6, 7).”
BackgroundIn silico structure-based approaches to discover protein-protein interaction-targeting drugs
Shin, W.-H., Christoffer, C. W., & Kihara, D. (2017) · Methods · doi:10.1016/j.ymeth.2017.08.006 · Cited by 82
G protein-coupled receptor microarrays for drug discovery
Ye, F., Lahiri, J., & Picard, L. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02779-x · Cited by 99
Roth, B. L., & Kroeze, W. K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.654764 · Cited by 88
“G-protein-coupled receptors (GPCRs;(2) 7-transmembrane domain receptors) historically have represented both the most abundant and the most popular gene superfamily for therapeutic drug discovery and development, with perhaps 30 – 40% of approved drugs targeting the non-olfactory GPCRs (1, 2).”
BackgroundComputational toxicology: an overview of the sources of data and of modelling methods
Nigsch, F., Macaluso, M., Mitchell, J. B. O., & Zmuidinavicius, D. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802660467 · Cited by 95
“With the sequences represented by various physicochemical property descriptors, for example, hydrophobicity and charge, the algorithm correctly distinguished known druggable from non-druggable proteins 84% of the time [94] .”
BackgroundBioinformatics and variability in drug response: a protein structural perspective
Lahti, J. L., Tang, G. W., Capriotti, E., Liu, T., & Altman, R. B. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2011.0843 · Cited by 89
Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic
Lencz, T., & Malhotra, A. K. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.28 · Cited by 91
Mass spectrometry accelerates membrane protein analysis
Savas, J. N., Stein, B. D., Wu, C. C., & Yates, J. R. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.04.005 · Cited by 103
Flanagan, J. M., Funes, J. M., Henderson, S. R., Wild, L., Carey, N., & Boshoff, C. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0636 · Cited by 95
“There have been numerous attempts of in silico prediction of cancer drug targets including structural analyses of all known proteins to define ‘‘the druggable genome,’’ which converges on 2,000 to 3,000 targets that contain protein folds that are amenable to drug-like small chemical compounds (3, 4).”
BackgroundSikander, R., Ghulam, A., & Ali, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-09484-3 · Cited by 88
“The “estimator” is used to generate the number of trees, “eta” regulates the learning rate, “max depth” controls the depth of the tree, “lambda” is used to avoid the overfitting, and “alpha” shrinks the high (1) f (m, n) = Tmn”
MethodStimuli-activatable PROTACs for precise protein degradation and cancer therapy
Gao, J., Yang, L., Lei, S., Zhou, F., Nie, H., Peng, B., Xu, T., Chen, X., Yang, X., Sheng, C., et al. (2023) · Science Bulletin · doi:10.1016/j.scib.2023.04.028 · Cited by 87
Conn, P. J., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301638 · Cited by 92
Peptide arrays for kinome analysis: New opportunities and remaining challenges
Arsenault, R. J., Griebel, P. J., & Napper, S. (2011) · PROTEOMICS · doi:10.1002/pmic.201100296 · Cited by 87
“Fortuitously, the conserved catalytic cleft of the kinases is highly attractive for drug design making the kinases highly ‘‘druggable’’ [8].”
BackgroundPeptide to Peptoid Substitutions Increase Cell Permeability in Cyclic Hexapeptides
Schwochert, J., Turner, R., Thang, M., Berkeley, R. F., Ponkey, A. R., Rodriguez, K. M., Leung, S. S. F., Khunte, B., Goetz, G., Limberakis, C., et al. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b01162 · Cited by 85
Anti-Inflammatory Agents as Cancer Therapeutics
Kashfi, K. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57002-5 · Cited by 94
Genomics and Cardiac Arrhythmias
Roberts, R. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.059 · Cited by 100
Husain, B., Ramani, S. R., Chiang, E. Y., Lehoux, I. E., Paduchuri, S., Arena, T. A., Patel, A., Wilson, B., Chan, P., Franke, Y., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001433 · Cited by 92
Hazell, G. G. J., Hindmarch, C. C., Pope, G. R., Roper, J. A., Lightman, S. L., Murphy, D., O’Carroll, A.-M., & Lolait, S. J. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2011.07.002 · Cited by 88
“It is estimated that 80% of all known hormones and neurotransmitters activate cellular signal transduction mechanisms via GPCRs [21], and a substantial portion (estimates vary between 30% and 60%) of current pharmaceutical agents directly or indirectly act on these receptors [130,205] – angiotensin II and aminergic (a…”
Fragment Based Drug Discovery: Practical Implementation Based on 19F NMR Spectroscopy
Jordan, J. B., Poppe, L., Xia, X., Cheng, A. C., Sun, Y., Michelsen, K., Eastwood, H. A., Schnier, P. D., Nixey, T. E., & Zhong, W. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201441k · Cited by 86
Targeting the DNA damage response for cancer therapy
Powell, S. N., & Bindra, R. S. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.04.011 · Cited by 92
Bioconjugates for targeted delivery of therapeutic oligonucleotides
Ming, X., & Laing, B. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.002 · Cited by 88
“Small-molecule drugs can only target certain classes of proteins including G protein-coupled receptors, ion channels, enzymes, and nuclear hormone receptors [1], while the targets for antibody drugs are limited to cell-surface receptors and circulating proteins.”
Cell-surface proteomics for the identification of novel therapeutic targets in cancer
Kuhlmann, L., Cummins, E., Samudio, I., & Kislinger, T. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1429924 · Cited by 81
Bojadzic, D., & Buchwald, P. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180531092503 · Cited by 82
“Only at the intersection of these two subsets (“druggable” and “disease modifying”) do true potential drug targets exist, with an estimated 500 to 1,500 members (Figure 1) [15, 16].”
BackgroundLuo, M., Lee, L. K. C., Peng, B., Choi, C. H. J., Tong, W. Y., & Voelcker, N. H. (2022) · Advanced Science · doi:10.1002/advs.202201740 · Cited by 92
Kant, S., Deepika, & Roy, S. (2025) · Discover Pharmaceutical Sciences · doi:10.1007/s44395-025-00007-3 · Cited by 104
One Crystal, Two Temperatures: Cryocooling Penalties Alter Ligand Binding to Transient Protein Sites
Fischer, M. M., Shoichet, B. K., & Fraser, J. S. (2015) · ChemBioChem · doi:10.1002/cbic.201500196 · Cited by 85
Computational analysis of ligand relationships within target families
Bajorath, J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.01.044 · Cited by 92
Can we discover pharmacological promiscuity early in the drug discovery process?
Peters, J., Hert, J., Bissantz, C., Hillebrecht, A., Gerebtzoff, G., Bendels, S., Tillier, F., Migeon, J., Fischer, H., Guba, W., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.001 · Cited by 91
Druggability of Intrinsically Disordered Proteins
Joshi, P., & Vendruscolo, M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-20164-1_13 · Cited by 86
“However, attempts at developing small molecule drugs that block protein-protein interactions have generally been challenging (Arkin and Wells 2004; Wells and McClendon 2007; Hopkins and Groom 2002).”
Background
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.